Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Percheron Therapeutics ( (AU:PER) ) is now available.
Percheron Therapeutics has announced new preclinical data demonstrating the activity of its investigational cancer drug, HMBD-002, in treating triple-negative breast cancer (TNBC). This research, conducted by the University of Texas Southwestern Medical Center, highlights the drug’s potential to inhibit tumor growth in VISTA-expressing TNBC, a particularly aggressive and treatment-resistant form of cancer. The findings suggest that HMBD-002 could offer a new avenue for addressing the unmet clinical needs of TNBC patients, potentially differentiating itself from existing immunotherapies by also modulating growth signals. The company plans to further evaluate HMBD-002’s development and expects to share phase I data by the end of 2025.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for oncology and rare diseases.
Average Trading Volume: 2,296,306
Technical Sentiment Signal: Sell
Current Market Cap: A$9.79M
See more data about PER stock on TipRanks’ Stock Analysis page.